These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 7908879)
1. Physiologically based pharmacokinetic (PBPK) modeling of piroxicam with regard to CYP2C9 genetic polymorphism. Cho CK; Kang P; Park HJ; Ko E; Mu CY; Lee YJ; Choi CI; Kim HS; Jang CG; Bae JW; Lee SY Arch Pharm Res; 2022 May; 45(5):352-366. PubMed ID: 35639246 [TBL] [Abstract][Full Text] [Related]
2. Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations. Tantishaiyakul V; Suknuntha K; Vao-Soongnern V AAPS PharmSciTech; 2010 Jun; 11(2):952-8. PubMed ID: 20512435 [TBL] [Abstract][Full Text] [Related]
3. Crystal structure transformations and dissolution studies of cimetidine-piroxicam coprecipitates and physical mixtures. Tantishaiyakul V; Songkro S; Suknuntha K; Permkum P; Pipatwarakul P AAPS PharmSciTech; 2009; 10(3):789-95. PubMed ID: 19521782 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. Brouwers JR; de Smet PA Clin Pharmacokinet; 1994 Dec; 27(6):462-85. PubMed ID: 7882636 [TBL] [Abstract][Full Text] [Related]
6. The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders. Milligan PA; McGill PE; Howden CW; Kelman AW; Whiting B Eur J Clin Pharmacol; 1993; 45(6):507-12. PubMed ID: 7908879 [TBL] [Abstract][Full Text] [Related]
7. Nizatidine versus cimetidine in the treatment of duodenal ulcers. Yap CK; Chong YY; Chia SC; Fock KM Ann Acad Med Singap; 1991 Mar; 20(2):241-3. PubMed ID: 1679316 [TBL] [Abstract][Full Text] [Related]
8. Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group. Cherner JA; Cloud ML; Offen WW; Latz JE Am J Gastroenterol; 1989 Jul; 84(7):769-74. PubMed ID: 2568086 [TBL] [Abstract][Full Text] [Related]
9. Safety issues relating to long-term treatment with histamine H2-receptor antagonists. Sabesin SM Aliment Pharmacol Ther; 1993; 7 Suppl 2():35-40. PubMed ID: 8103374 [TBL] [Abstract][Full Text] [Related]
10. [The effects of an H2 receptor antagonist (cimetidine) in asthmatic patients]. Kobayashi H; Adachi M; Takahashi T Arerugi; 1985 Jan; 34(1):23-32. PubMed ID: 2859846 [No Abstract] [Full Text] [Related]
11. [Effective prevention of piroxicam-induced lesions of the gastric mucosa with nizatidine]. Dammann HG; Simon-Schultz J; Dreyer M; Simon B; Müller P Z Gastroenterol; 1990 Feb; 28(2):94-6. PubMed ID: 1969684 [TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Leemann T; Transon C; Dayer P Life Sci; 1993; 52(1):29-34. PubMed ID: 8417277 [TBL] [Abstract][Full Text] [Related]
13. Cimetidine impairs the elimination of theophylline and antipyrine. Roberts RK; Grice J; Wood L; Petroff V; McGuffie C Gastroenterology; 1981 Jul; 81(1):19-21. PubMed ID: 7239117 [TBL] [Abstract][Full Text] [Related]
14. No significant effect of cimetidine on the pharmacokinetics of misonidazole in man. Begg EJ; Williams KM; Wade DN; O'Shea KF Br J Clin Pharmacol; 1983 May; 15(5):575-6. PubMed ID: 6860535 [No Abstract] [Full Text] [Related]